A new trading day began on Friday, with MoonLake Immunotherapeutics (NASDAQ: MLTX) stock price up 9.95% from the previous day of trading, before settling in for the closing price of $56.38. MLTX’s price has ranged from $31.42 to $61.87 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -319.65% over the past five years. Meanwhile, its annual earnings per share averaged -74.04%. With a float of $55.14 million, this company’s outstanding shares have now reached $63.47 million.
MoonLake Immunotherapeutics (MLTX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of MoonLake Immunotherapeutics is 13.16%, while institutional ownership is 91.93%. The most recent insider transaction that took place on Jul 03 ’25, was worth 1,146,565. In this transaction Director of this company sold 23,500 shares at a rate of $48.79, taking the stock ownership to the 0 shares. Before that another transaction happened on Jul 03 ’25, when Company’s Director proposed sale 23,500 for $48.79, making the entire transaction worth $1,146,595.
MoonLake Immunotherapeutics (MLTX) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.56 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -74.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.25% during the next five years compared to -319.65% drop over the previous five years of trading.
MoonLake Immunotherapeutics (NASDAQ: MLTX) Trading Performance Indicators
Here are MoonLake Immunotherapeutics’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 16.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.79, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -4.04 in one year’s time.
Technical Analysis of MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (NASDAQ: MLTX) saw its 5-day average volume 0.71 million, a positive change from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 83.23%.
During the past 100 days, MoonLake Immunotherapeutics’s (MLTX) raw stochastic average was set at 97.15%, which indicates a significant increase from 93.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.18 in the past 14 days, which was higher than the 2.26 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.63, while its 200-day Moving Average is $46.43. Nevertheless, the first resistance level for the watch stands at $64.27 in the near term. At $66.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $70.34. If the price goes on to break the first support level at $58.20, it is likely to go to the next support level at $54.40. The third support level lies at $52.13 if the price breaches the second support level.
MoonLake Immunotherapeutics (NASDAQ: MLTX) Key Stats
With a market capitalization of 3.98 billion, the company has a total of 64,231K Shares Outstanding. Currently, annual sales are 0 K while annual income is -118,940 K. The company’s previous quarter sales were 0 K while its latest quarter income was -55,220 K.
